ANIX · Anixa Biosciences Inc
United States · RS rating 49 · As of 2026-11-03
| Price | 3.06 USD |
|---|---|
| 1-day change | +2.2% |
| RS rating (overall / 1M / 3M / 12M) | 49 / 68 / 45 / 33 |
| Stage | Topping |
| Composite / Minervini / CANSLIM score | 24 / 16 / 39 |
| Industry group (rank) | Medical-Biomed/Biotech (154) |
| EPS growth Q/Q | +12.5% |
| Sales growth Q/Q | – |
| Distance from 52-week high | +41.5% |
| Market cap (USD) | $101.9M |